Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approves PREVYMIS for CMV Disease Prevention in High-Risk Kidney Transplant
Details : Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.
Product Name : Prevymis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2024
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex.
Product Name : Prevymis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from The USFDA for Acyclovir Cream
Details : Acyclovir is a synthetic purine nucleoside analogue having high affinity for the enzyme thymidine kinase encoded by HSV and VZV. It has shown in vitro and in vivo inhibitory activity against herpes simplex virus types 1, 2 and varicella-zoster virus (VZV...
Product Name : Zovirax-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Advisory - Apotex Recalls Apo-Acyclovir Tablets Due to a Nitrosamine Impurity
Details : Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
Product Name : Apo-Acyclovir
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : ANI Pharmaceuticals Inc
Deal Size : $372.5 million
Deal Type : Acquisition
Details : Novitium Pharma's lead drug, Acyclovir oral suspension, is a synthetic nucleoside analogue active against herpesviruses. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $89.5 million
September 03, 2021
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : ANI Pharmaceuticals Inc
Deal Size : $372.5 million
Deal Type : Acquisition
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Padagis
Deal Size : $21.0 million
Deal Type : Partnership
Details : Under the new Agreement, Sol-Gel has retained collaboration rights to two generic programs acyclovir cream and ivermectin cream related to four generic drug candidates that it believes to have the most value-generating potential.
Product Name : Acyclovir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 11, 2021
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Padagis
Deal Size : $21.0 million
Deal Type : Partnership
Lead Product(s) : Aciclovir,Hydrocortisone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Shijiazhuang Yuanmai Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement gives SYB the right to register, manufacture and market the product in China.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 24, 2020
Lead Product(s) : Aciclovir,Hydrocortisone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Shijiazhuang Yuanmai Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
